Simon Collins is an HIV positive treatment advocate who works to encourage people living with HIV to take an active role in their own health. He was lucky enough to be access combination therapy in 1996 which he started with a CD4 count in single figures.
“HIV positive people should have the choice to be actively involved and represented at all levels of their care. Free access to the latest information should be available to everyone before we make treatment decisions about our health.”
Simon co-ordinates the i-Base treatment information services including the phoneline and the website. Since February 2003 he has edited HIV Treatment Bulletin and he also edits the i-Base treatment guides and the treatment training manual for advocates. Producing copyright-free publications has helped enabled information from these resources be translated into over 35 languages.
He is involved in developing community involvement in clinical research and treatment guidelines. He has been on the writing committee for several BHIVA (UK) and EACS (European) guidelines. He a member of the Drugs Sub Group for London HIV commissioners and on the Drugs Advisory Group for HIV Clinical Reference Group (CRG) for NHS England).
For two years, he co-co-chaired the European Community Advisory Board (ECAB) and in 2002 cofounded the UK-CAB which now has over 800 members. Also in 2002, he gave evidence to the UK parliamentary health committee on sexual health and in 2016 he contributed to the discussions at the United Nations in New York on universal access to ART.
He is involved as a community representative on several current research studies.
- ASTRA (large cross-sectional questionnaire study about HIV treatment, lifestyle and transmission in HIV positive people in the UK).
- AURAH (large cross sectional questionnaire study similar to ASTRA but in HIV negative people attending sexual health clinics in the UK).
- CHERUB (UK collaboration of researchers working on aspects of HIV cure research that includes the REACH and RIVER studies).
- CIPHER (a sub-study or ASTRA looking at cognitive function and brain-related disorders).
- COBRA (collaborative EU research on HIV and ageing).
- D:A:D study (the largest prospective international database study looking at side effects of HIV drugs and impact of other complications).
- HALL study (social science research looking at issue of HIV in later life).
- HIPvac (randomised study comparing approaches including a vaccine to treating genital warts, predominantly in HIV negative adults).
- HIV Drug Resistance Database – Ongoing database that now has more than 125,000 resistance test sequences collected in the UK since 2001. This research resource answers important questions on drug resistance.
- INSIGHT group (including the START study – see below).
- PANTHEON – programme of research into cost-effectiveness of strategies including self-testing to reduce HIV transmission (SELPHI study).
- LEAP – Long-Acting Extended Release ARV Resource Programe
- PARTNER and PARTNER2 studies (risk of HIV transmission in sero-different couples where the HIV positive partner is taking HIV meds and has an undetectable viral load – and who do not always use condoms. PARTNER reported zero HIV transmissions after couples in the study had sex more than 58,000 times without condoms. PARTNER2 continues in gay men.
- POPPY (UK study on HIV and ageing).
- PROUD study (UK PrEP study using daily oral tenofovir/FTV to prevent HIV infection in HIV negative gay men and transgender women).
- RIVER study – trying to reduce the latently infected viral reservoir in people who were recently infected. This study related to cure research involves a treatment interruption.
- START study (a large international randomised study looking at when to start HIV treatment based on CD4 counts above 500 or waiting to 350 cells/mm3). Results showed the ART can reduced serious HIV-related illnesses even at high CD4 counts and led to changes in treatment guidelines to routinely recommended ART for all.
- SUPA (interventional option to help adherence).
- TAILoR study (randomised study looking at use of telmisartan and insulin resistance in HIV positive people).
- UK-CHIC (prospective database that includes anonymised medical history from over 45,000 HIV positive people in the UK).
- UK Seroconverters Register (prospective UK cohort of people diagnosed within a year of infection).
- Member of the external advisory panel for Liverpool Biomedical Research Centre from 2007-2012.
Simon co-founded HIV i-Base in 2000 with colleagues from the AIDS Treatment Project in London where he volunteered and worked in various positions from 1997-2000 including as a peer advocate and director.
In addition to i-Base publications he is a contributing author on the following papers, guidelines and conference abstracts.
Depression, self-efficacy, and sexual behaviour among men who have sex with men. Miltz A, Rodger A, Sewell J, Speakman A, Phillips A, Sherr L, Gilson R, Asboe D, Nwokolo N, Clarke A, Allan S, Collins S, Lampe F, for the AURAH (Attitudes to and Understanding of Risk of Acquisition of HIV) Study Group. HIV Research for Prevention Conference (HIVR4P), 17-20 October 2016, Chicago. Poster 21.
Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment. J Sewell, M Daskalopoulou, F Nakagawa, FC Lampe, S Edwards, N Perry, E Wilkins, R O’Connell, M Jones, S Collins, A Speakman, AN Phillips, AJ Rodger for the ASTRA Study Group. HIV Medicine 2016, December 2016. DOI: 10.1111/hiv.12477.
Socio-economic disadvantage and viral load outcomes for HIV positive people on antiretroviral treatment in the UK: cross-sectional and longitudinal analysis. LS Burch, CJ Smith, J Anderson, L Sherr, AJ Rodger, R O’Connell, AM Geretti, R Gilson, M Fisher, J Elford, M Jones, S Collins, Y Azad, AN Phillips, A Speakman, MA Johnson, FC Lampe for the ASTRA Study Group. Lancet Public Health 2016, Published Online October 12, 2016.
Non-disclosure of HIV status and associations with psychological factors, ART non-adherence and viral load non-suppression among people living with HIV in the UK. M Daskalopoulou, FC Lampe, L Sherr, AN Phillips, MA Johnson, R Gilson, N Perry, E Wilkins, M Lascar, S Collins, G Hart, A Speakman, AJ Rodger for the ASTRA Study Group. AIDS and Behaviour 2016, in press
Increased risk of suicidal behaviour with use of efavirenz: results from the START trial. A Arenas-Pinto, B Grund, S Sharma, E Martinez, N Cummins, J Fox, KL Klingman, D Sedlacek, S Collins, PM Flynn, WM Chasanov, E Kedem, C Katlama, J Sierra-Madero, V Ormaasen, P Brouwers, D Cooper, for the INSIGHT START Study Group. 21st World AIDS Conferences (AIDS2016), 18-22 July 2016, Durban, South Africa. Oral abstract THAB0202.
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J, for the PARTNER Study Group. JAMA, 2016;316(2):1-11. DOI: 10.1001/jama.2016.5148. (12 July 2016).
No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom. Ellen White, Erasmus Smit, Duncan Churchill, Simon Collins, Clare Booth, Anna Tostevin, Caroline Sabin, Deenan Pillay, and David T. Dunn; on behalf of the UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study. Journal of Infectious Diseases. (2016). DOI: 10.1093/infdis/jiw213. (24 May 2016).
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. A Tostevin, E White, D Dunn, S Croxford, V Delpech, I Williams, D Asboe, A Pozniak, D Churchill, AM Geretti, D Pillay, C Sabin, A Leigh-Brown and E Smit for the UK HIV Drug Resistance Database. HIV Medicine (2016). DOI: 10.1111/hiv.12414.
Age, time living with diagnosed HIV infection, and self-rated health. McGowan J, Sherr L, Rodger A, Fisher M, Miners A, Anderson J, Johnson M, Elford J, Collins S, Hart G, Phillips A, Speakman A, Lampe F and the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group (2016). HIV Med. doi:10.1111/hiv.12398. Online July 2016, print January 2017.
Age and life course location as interpretive resources for decisions regarding disclosure of HIV to parents and children: Findings from the HIV and later life study. Rosenfeld D, Ridge D, Catalan J, Delpech V, on behalf of the HIV Later Life (HALL) team. Journal of Aging Studies 38 (2016) 81–91.
The AURAH 2 Study: Attitudes to and understanding of risk of acquisition of HIV over time: design and methods for an internet-based prospective cohort study among UK men who have sex with men. Sewell J, Speakman A, Phillips AN, Cambiano V, Lampe FC, Gilson R, Asboe D, Nwokolo N, Clarke A, Ogilvy A, Collins S, Rodger AJ. JMIR Research. JMIR Res Protoc 2016;5(2):e128. doi:10.2196/resprot.5582.
Sexual behaviour among people with HIV according to self-reported antiretroviral and viral load status: results from the antiretrovirals sexual transmission risk attitudes study. Lampe F et al for ASTRA Study Group. AIDS. (2016) AIDS 2016, 30: 1745-1759. DOI:10.1097/QAD.0000000000001104.
A global survey of HIV-positive people’s attitudes towards cure research. Simmons R, Kall M, Collins S, Cairns G, Taylor S, Nelson M, Fidler S, Porter K and Fox J on behalf of the Collaborative HIV Eradication of viral Reservoirs (CHERUB) Survey collaboration
. HIV Medicine (2016). DOI: 10.1111/hiv.12391. Online May 2016, print January 2017.
HIV treatment information and advocacy 2014/15: continued demand for community support services. R Jakob, R Trevelion, J Dunworth, M Sachikonye and S Collins. 22nd Annual BHIVA Conference, 19-22 April 2016, Manchester. Oral abstract O5. HIV Medicine, 17 (Suppl. 1), 3–13.
Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. M Daskalopoulou, AJ Rodger, AN Phillips, A Speakman, FC Lampe, J McDonnell, AM Johnson, L Sherr, J Elford, N Perry, E Wilkins, S Collins and WJ Burman. 22nd Annual BHIVA Conference, 19-22 April 2016, Manchester. Oral abstract O18. HIV Medicine, 17 (Suppl. 1), 3–13.
Accuracy of reporting undetectable HIV viral load among people with HIV on antiretroviral treatment. J Sewell, M Daskalopoulou, F Nakagawa, FC Lampe, A Speakman, AN Philllips, AJ Rodger, S Edwards, N Perry, E Wilkins, R O’Connell, M Jones and S Collins. 22nd Annual BHIVA Conference, 19-22 April 2016, Manchester. Poster abstract P144. HIV Medicine, 17 (Suppl. 1), 14–71.
A cross-sectional study on attitudes to and understanding of risk of acquisition of HIV: design, methods and participant characteristics. Sewell J, Speakman A, Phillips AN, Lampe FC, Miltz A, Gilson R, Asboe D, Nwokolo N, Scott C, Day S, Tang A, Tariq Sadiq S, Taylor S, Collins S, Sherr L, Hart G, Johnson AM, Miners A, Elford J, Rodger A. JMIR Research Protocols 2016;5(2):e58. DOI:10.2196/resprot.4873.
Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. Phillips AN, Cambiano V, Alec Miners A, Lampe FC, Rodger A, Nakagawa F, Brown A, Gill N, De Angelis D, Elford J, Graham Hart G, Johnson AM, Lundgren JD, Collins S, Delpech D. AIDS 2015, 29:1855–1862. September 2015.
Initiation of antiretroviral therapy in early asymptomatic HIV infection. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina J-M, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. NEJM 2015; 373(9):795-802. (27 August 2015).
The Impact of HCV infection duration on HIV disease progression and response to cART amongst HIV seroconverters in the UK. Jamie Inshaw, Clifford Leen, Martin Fisher, Richard Gilson, David Hawkins, Simon Collins, Julie Fox, Ken McLean, Sarah Fidler, Andrew Phillips, Sam Lattimore, Abdel Babiker, Kholoud Porter. PLoS ONE 10(7): e0132772. doi:10.1371/journal.pone.0132772. (August 2015).
Patient information leaflets (PILs) currently require, graduate-level reading skills equivalent to The Guardian or The Telegraph. S Collins, L Martin, R Jakob, M Williams and M Boffito. 21st Annual BHIVA Conference, 21-24 April 2015, Brighton. Oral abstract O4. HIV Medicine, 16 (Suppl. 2), 1–11.
UK clinicians’ approach to ART in primary HIV infection; comparison with the BHIVA guidelines. V Parsons, A Phillips, R Gilson, G Hart, K Porter, S Fidler, N Fitzgerald, J Fox and S Collins. 21st Annual BHIVA Conference, 21-24 April 2015, Brighton. Oral abstract O13. HIV Medicine, 16 (Suppl. 2), 1–11.
Attitudes, beliefs and acceptability towards early ART amongst men who have sex with men (MSM) recruited to a UK cohort of HIV seroconverters. V Parsons, A Phillips, R Gilson, G Hart, K Porter, A Johnson, S Fidler, J Fox, M Fisher, D Hawkins, K McLean, M Johnson and S Collins. 21st Annual BHIVA Conference, 21-24 April 2015, Brighton. Poster abstract P33. HIV Medicine, 16 (Suppl. 2), 12–77.
A UK survey of HIV-positive people’s attitudes towards cure research, R Simmons1, K Porter, M Kall, S Collins, G Cairns, S Taylor, M Nelson, S Fidler and J Fox. 21st Annual BHIVA Conference, 21-24 April 2015, Brighton. Poster abstract P39. HIV Medicine, 16 (Suppl. 2), 12–77.
Altruism and medical advice are key factors in decision- making about participating in HIV cure research: Results from a UK-wide survey of people living with HIV. M Kall, R Simmons, S Collins, G Cairns, S Taylor, M Nelson, S Fidler, K Porter and J Fox for the CHERUB Collaboration. 21st Annual BHIVA Conference, 21-24 April 2015, Brighton. Poster abstract P159. HIV Medicine, 16 (Suppl. 2), 12–77.
Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. N Geffen, P Aagaard, GM Corbelli, M Meulbroek, D Peavy, C Rappoport, S Schwarze, S Collins. HIV Medicine Special Issue: The START Trial Characteristics at Study Entry. April 2015. 16(S1):10–13. DOI: 10.1111/hiv.12228.
K65R detected more frequently in HIV-1 subtype C viruses at virological failure. E Smit, E White, D Clark, D Churchill, H Zhang, S Collins, D Pillay, A Tostevin, D Dunn, on behalf of UKHDRD and UKCHIC. Conference on Retroviruses and Opportunistic Infectons (CROI) 2015, 23-26 February 2015, Seattle, Washington. Poster abstract 596.
K65R detected more frequently in HIV-1 subtype C viruses at virological failure. E Smit, E White, D Clark, D Churchill, H Zhang, S Collins, D Pillay, A Tostevin, D Dunn, on behalf of UKHDRD and UKCHIC. XXIV International HIV Drug Resistance Workshop , 21-22 February 2015, Seattle, Washington. Poster abstract 89.
A community perspective on pre-exposure prophylaxis. Collins S. HIV Drug Therapy Glasgow Congress 2014, Oral abstract O334. Journal of the International AIDS Society 2014, 17(Suppl 3):19522.
Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK. McGowan J, Sherr L, Rodger A, Fisher M, Miners A, Johnson M, Elford J, Collins S, Hart G, Phillips A, Speakman A, Lampe F. HIV Drug Therapy Glasgow Congress 2014, Poster abstract P098. Journal of the International AIDS Society 2014, 17(Suppl 3):19511.
Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA study. Daskalopoulou M, Rodger A, Thornton A, Phillips AN, Sherr L, Gilson R, Johnson M, Fisher M, Anderson J, McDonnell J, Edwards S, Perry N, Collins S, Bhagani S, Speakman A, Smith C, Lampe F. HIV Drug Therapy Glasgow Congress 2014, Oral abstract O314. Journal of the International AIDS Society 2014, 17(Suppl 3):19630. http://www.jiasociety.org/index.php/jias/article/view/19630
Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Miners A et al for ASTRA study. The Lancet HIV, Early Online Publication, 23 September 2014 doi:10.1016/S2352-3018(14)70018-9
Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Daskalopoulou M, Rodger A, Phillips AN, Sherr L, Speakman A, Collins S, Elford J, Johnson MA, Gilson R, Fisher M, Wilkins E, Anderson J, McDonnell J, Edwards S, Perry N, O’Connell R, Lascar M, Jones M, Johnson AM, Hart G, Miners A, Geretti A-M, Burman WJ, Lampe FC. The Lancet HIV, Early Online Publication, 8 September 2014, doi:10.1016/S2352-3018(14)70001-3.
Minimal cognitive impairment in UK HIV positive men who have sex with men: effect of case definitions, and comparison with the general population and HIV negative men. McDonnell JM; Haddow L, Daskalopoulou M, Lampe F, Speakman A, Gilson R, Phillips A, Sherr L, Wayal S, Harrison J, Antinori A, Maruff P, Schembri A, Johnson M, Collins S, Rodger A, for the Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group. JAIDS, 2 July 2014. doi: 10.1097/QAI.0000000000000273.
British HIV Association guidelines for HIV-associated malignancies 2014. M Bower (Chair), A Palfreeman (Vice Chair), M Alfa-Wali, C Bunker, F Burns, D Churchill, S Collins, K Cwynarski, S Edwards, P Fields, K Fife, E Gallop-Evans, S Kassam, R Kulasegaram, Prof Charles Lacey, Dr R Marcus, S Montoto, M Nelson, T Newsom-Davis, C Orkin, K Shaw, M Tenant-Flowers, A Webb, S Westwell, M Williams. HIV Medicine (2014), 15 (Suppl. 2), 1–92. DOI: 10.1111/hiv.12136.
Attitudes of people in the UK with HIV who are antiretroviral (ART) naïve to starting ART at high CD4 counts for potential health benefit or to prevent HIV transmission. Rodger AJ, Phillips A, Speakman A, Gilson R, Fisher M, Wilkins E, Anderson J, Johnson M, O’Connell R, Collins S, Elford J, Sherr L, Lampe FC, for the ASTRA (Antiretrovirals, Sexual Transmission Risk and Attitudes) Study Group. PLoS ONE 2014 9(5): e97340. (28 May 2014). doi: 10.1371/journal.pone.0097340
Temporal trends in cART initiation amongst HIV seroconverters in the UK, V Parsons, A Phillips, R Gilson, S Fidler, J Fox, M Fisher, A Johnson, D Hawkins, K McLean, M Johnson, S Collins, G Hart and K Porter. 3rd Joint BHIVA/ BASHH Conference, 1-4 April 2014. Oral abstract O8.
HIV and health-related quality-of-life in the UK – where are we now? A Miners, A Rodger, A Speakman, A Phillips, M Fisher, J Anderson, S Collins, G Hart, L Sherr and F Lampe. 3rd Joint BHIVA/ BASHH Conference, 1-4 April 2014. Oral abstract O9.
Community, scientific and medical collaboration to develop a new generation of activists: results of a four-day workshop. D Kelly, S Collins, R James, S Petretti, M Platt and M Sachikonye, 3rd Joint BHIVA/ BASHH Conference, 1-4 April 2014. Poster abstract P196.
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. Dolling D, Hué S, Delpech V et al for The UK Collaborative Group on HIV Drug Resistance. AIDS 2014, 28:773–780. DOI:10.1097/QAD.0000000000000119.
HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. Rodger A, Bruun T, Cambiano V, Vernazza P, Estrada V, Van Lunzen J, Collins S, Geretti AM, Phillips A, Lundgren J, for the PARTNER Study Group. 21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston. Late breaker oral abstract 153LB.
Community views: balancing the public health benefits of earlier antiretroviral treatment with the implications for individual patients – perspectives from the community. Collins S and Geffen N. Curr Opin HIV AIDS, January 2014; 9(1);4-10. DOI:10.1097/COH.0000000000000024.
Persistence of HIV-1 Transmitted Drug Resistance Mutations. Castro H, Pillay D, Cane P et al. for the UK Collaborative Group on HIV Drug Resistance. Journal of Infectious Diseases 208(9):1459-1463. (November 2013).
Recreational drug use and high risk sexual behaviour among HIV-diagnosed men who have sex with men (MSM) in the UK: results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) study. Daskalopoulou M, Phillips A, Rodger A, Sherr L, Speakman A, Gilson R, Johnson MA, Fisher M, Wilkins E, Anderson J, O’Connell R, Lascar M, Jones M, Edwards S, McDonnell J, Perry N, Collins S, Hart G, Johnson A, Elford J, Miners A, Geretti AM, Burman B, Lampe F. 14th EACS, 16-19 October 2103, Brussels. Oral abstract PS 11/3.
The ‘Antiretrovirals, Sexual Transmission Risk and Attitudes’ (ASTRA) Study. Design, Methods and Participant Characteristics. Speakman A, Rodger A, Phillips AN, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, O’Connell R, Lascar M, Aderogba K, Edwards S, McDonnell J, Perry N, Sherr L, Collins S, Hart G, Johnson AM, Miners A, Elford J, Geretti A-M, Burman WJ, Lampe FC. PLoS ONE 8(10): e77230. doi:10.1371/journal.pone.0077230, Published 15 Oct 2013.
Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. Rodger AJ, Bruun T, Vernazza P, Collins S, Estrada V, Van Lunzen J, Corbelli GM, Phillips AN, Lundgren JD; PARTNER Study Group. Antivir Ther. 2013;18(3):285-7. doi: 10.3851/IMP2609. Epub 2013 Apr 24.
Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. Sabin, Caroline A; Cooper, David A; Collins, Simon; Schechter, Mauro. AIDS. Post acceptance, 11 March 2013 doi: 10.1097/QAD.0b013e328360d546.
ART-naive individuals’ attitudes to starting ART at high CD4 counts for potential health benefit or to prevent HIV transmission. Rodger A, A Phillips, A Speakman, R Gilson, M Fisher, E Wilkins, J Anderson, S Collins, L Sherr, F Lampe, and ASTRA Study Group. 20th CROI, 3-6 March 2013, Atlanta, Georgia, USA. Poster 1038.
Budget issues driving/affecting treatment choice. Collins S. 11th International Congress on HIV Infection. 11-15 November 2012. Session: A Community Perspective on How To Treat Europe. Oral presentation. Tuesday 13 November, 2012.
ART use, viral suppression, and sexual behaviour among HIV-diagnosed MSM in the UK: results from the ASTRA (Antiretrovirals, Sexual Transmission Risk and Attitudes) Study. Lampe FC, Speakman A, Phillips AN, Sherr L, Gilson R, Johnson MA, Fisher M, Wilkins E, Anderson J, Edwards S, McDonnell J, Perry N, Aderogba K, Hart G, Johnson A, Collins S, Elford J, Miners A, Geretti A, Burman B, Rodger A for the ASTRA Study Group. 11th International Congress, Glasgow, 2012. Oral abstract O323.
Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers. C Foreman, B Gazzard, M Johnson, P Sharott, S Collins. Sexually transmitted infections. 03/2012; 88(2):112-115. doi:10.1136/sextrans-2011-050438.
Partners of people on ART – a New Evaluation of the Risks (The PARTNER study): design and methods. Alison Rodger, Tina Bruun, Matthew Weait, Pietro Vernazza, Simon Collins, Vicente Estrada, Jan Van Lunzen, Giulio Maria Corbelli, Fiona Lampe, Andrew Phillips, Jens Lundgren and The PARTNER study group. BMC Public Health 2012, 12:296.
Why it is time to say goodbye to stavudine … everywhere. Isabelle Andrieux-Meyer, Polly Clayden, Simon Collins, Nathan Geffen, Eric Goemaere, Mark Harrington, Sharonann Lynch, Tido von Schoen-Angerer, Tracy Swan. Southern African Journal of HIV Medicine, Vol 13, No 1 (2012).
Depression and virological status among UK HIV outpatients: results from a multicentre study. Lampe F, Speakman A, Phillips AN, Sherr L, Gilson R, Johnson M, Fisher M, Anderson J, Wilkins E, Broussard C, McDonnell J, Perry N, Scourse R, George V, Hart G, Johnston A, Rodger A, George V, Collins S, Miners A, Elford J, Geretti A, Burman B, ASTRA Study. 19th International AIDS Conference, 22-25 July 2012, Washington. Poster abstract WEPE075.
4th generation (Ag/Ab) HIV testing: 47% clinics contradict current guidelines. Rezel E, Walker C, Collins S. 18th Annual BHIVA Conference, 18–20 April 2012. Oral abstract O21. HIV Medicine Volume 13, Supplement s1; 1-11. April 2012.
Depression and virological status among UK HIV outpatients: results from a multicentre study. Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Anderson J, Wilkins E, Broussard C, McDonnell J, Perry N, Scourse R, George V, Hart G, Johnson A, Collins S, Miners A, Elford J, Geretti A-M, Burman W and Rodger A. 18th Annual BHIVA Conference, 18–20 April 2012. Oral abstract O10. HIV Medicine Volume 13, Supplement s1; 1-11. April 2012.
Understanding why serodifferent couples do not always use condoms when the HIV+ partner is on ART. Rodger A, Bruun T, Vernazza P, Collins S, Estrada V, Van Lunzen J, Viciana P, Corbelli GM, Phillips A, Lundgren J, for the PARTNER Study Group. 19th Conference on Retroviruses and Opportunistic Infections, 5–8 March 2012. Poster abstract 564.
Transmission rates of HIV on antiretroviral therapy (ART): unanswered questions. Rodger A, Bruun T, Vernazza P, Collins S, Estrada V, Van Lunzen J, Corbelli GM, Holllander L, Ellefson M, Phillips A, Lundgren J. 13th European AIDS Conference, 2011, Belgrade. Poster LBPE 16.2/4.
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. Lundgren JD et al for the EACS Executive Committee. October 2011.
British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. Writing Group AL Pozniak, KM Coyne, RF Miller, MCI Lipman, AR Freedman, LP Ormerod, MA Johnson, S Collins and SB Lucas on behalf of the BHIVA Guidelines Subcommittee. HIV Medicine (2011), 12, 517–524.
HIV-positive vs HIV-infected: reducing barriers to clinical research though appropriate and accurate language. Collins S, Swan T, Franquet X. XVIII Intl AIDS Conference, 18–23 July 2010, Vienna, Austria. Poster TUPE0516.
British HIV Association guidelines for HIV-associated malignancies (2008). Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N, Webb A, on behalf of the AIDS Malignancy Subcommittee. HIV Medicine, Volume 9, Issue 6, pages 336–388, July 2008.
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. Lundgren JD et al for the EACS Executive Committee. HIV Medicine Volume 9, Issue 2, pages 72–81, February 2008.
The dangers of attacking disease programmes for developing countries. Simon Collins, Brook K Baker, Gregg Gonsales, Marco Gomes. BMJ 2007; 335:646 doi: 10.1136/bmj.39349.591296.59 (Published 27 September 2007)
Treatment of HIV-infected adults with antiretroviral therapy. BHIVA Writing Committee : J Anderson, A Babiker, M Boffito, G Brook, D Churchill, S Collins, M Fisher, A Freedman, B Gazzard, AM Geretti, M Johnson, S Khoo, C Leen, D Nair, B Peters, A Phillips, D Pillay, A Pozniak, J Walsh, E Wilkins and I Williams. HIV Medicine (2005) 6 (Suppl. 2), 1–61.
BHIVA treatment guidelines for TB/HIV infection. February 2005. Pozniak AL, Miller RF, Lipman MCI, Freedman AR, Ormerod LP, Johnson MA, Collins S and Lucas SB, on behalf of the BHIVA guidelines writing committee.
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV-co-infected patients. Alberti A, Clumeck N, Collins S, et al, for the ECC Jury. J Hepatol. 2005;42:615-624.
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy, July 2003. BHIVA Writing Committee members: A Pozniak, B Gazzard, J Anderson, A Babiker, D Churchill, S Collins, M Fisher, M Johnson, S Khoo, C Leen, C Loveday, G Moyle, M Nelson, B Peters, A Phillips, D Pillay, E Wilkins, I Williams, M Youle.
Face-to-face negotiations for patients’ interests. P Marques, E Trenado, S Collins, F Houyez. 14th International AIDS Conference, 7-12 July 2002, Barcelona. Abstract no. MoPeB3264.
Last updated: 1 January 2017